SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia—a phase II randomised control trial study protocol

Peer review reports

Original Submission
10 Mar 2021	Submitted	Original manuscript
14 Jun 2021	Reviewed	Reviewer Report - Claire Cochran
Resubmission - Version 2
	Submitted	Manuscript version 2
Publishing
15 Jun 2021	Editorially accepted
5 Jul 2021	Article published	10.1186/s13063-021-05373-8

Back to article page